#4

PTO/SB/08A (04-03)

Copy

JUL 0 7 2003 W

Sheet 1

Approved for

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Complete if Known

 Application Number
 10/030,188

 Filing Date
 02/04/2002

 First Named Inventor
 Liebeschuetz, J. W.

 Art Unit
 1624

 Examiner Name
 Patel, Sudhaker B

 Attorney Docket Number
 00217/US

				DOCUMENTS		
ixaminer nitials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY		Patentee or ited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
87	<u>A1</u>	<sup>US-</sup> 5346907	09-13-1994	Kerwin et al	(	5141312 CX
	A2	<sup>US-</sup> 6545055	04-08-2003	Zhu et al	L	C14(613 1/1)
		US-				JECH CENTER 20
		US-				CH CO. 20
		US-				
		US-				1600/2
		US-				99/4
		US-			-	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

			IGN PATENT DOCU	MENTS	<u> </u>	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	1
800	B1	WO 99/11657 🍄	03-11-1999	Proteus 5		Ε
S	B2	WO 99/11658	03-11-1999	Proteus 4	<u> </u>	E
D0%	∠B3	WO 98/47876	10-29-1998	Akzo 5		Е
20	B4	WO 00/76971 ·	12-21-2000	Eli Lilly and Co		E
0,0	B5	WO 00/76970 '		Eli Lilly and Co		_
8	В6	WO 00/77027	n 12-21-2000	Protherics 6	<del></del>	

Examiner Signature Date Considered 10 5 03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nim of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



	FFICE 662						
	the Par	perwork Reduction Act of 1995, no persor	ons are required to re	U.S. Patent and Traden spond to a collection of informat	nark Office; U.		ĺ
				Application Number	10/030,1	88	
IN	FOI	RMATION DISCLOS	SUPF	Filing Date	02/04/20	02	
				First Named Inventor	Liebesch	nuetz, J. W. 4/	18, 10
S	IAI	EMENT BY APPLIC	JAN I	Art Unit	1624	5/1/20	7 <00 ≥
		(Use as many sheets as necessary)	`	Examiner Name	Patel, Su	ıdhaker B	1 "
Sheet	2	of 5		Attorney Docket Number	00217/U	S	60n
			II C DATENT	DOCUMENTS		<u> </u>	2000
miner	Cite	Document Number	Publication Date	Name of Patentee	or	Pages, Columns, Lines, Where	- <i>~</i>
als*	No.¹	2 (# known)	MM-DD-YYYY	Applicant of Cited Docu		Relevant Passages or Relevant	

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-		<del></del>	
		US-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	A PRODUCTION OF ORDER DOCUMENTS	Or Relevant Figures Appear	T <sup>6</sup>
Sign	В7	WO 91/00725	01-24-1991	Abbott Labs		
83%	B8	WO 99/00121	01-07-1999	Eli Lilly and Co	-	
800	B9	WO 99/00126	01-07-1999	Eli Lilly and Co 11		
M	B10	WO 99/00127		Eli Lilly and Co ( 2		$\equiv$
Ra	B11	WO 99/00128	01-07-1999	Eli Lilly and Co 、ろ		
<u> </u>	B12	WO 00/39092	07-06-2000	Eli Lilly and Co (4		

Examiner		$(\mathcal{L}_{\mathcal{L}})$	Date	12/6/07
Signature	W H W		Considered	
			<u> </u>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the region of the Emperor must precede the serial number of the patent document. Sind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Sheet 13

Approved for use through 04/30/2003. OMB 0551-031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMPERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control budger.

Substitute for form 1449/PTO

Application Number 10/030,188

Filing Date 02/04/2002

First Named Inventor Liebeschuetz, 1904

Patel, Sudhaker B

AT7/I IS

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code <sup>2 (# known)</sup>		-	Figures Appear
		US-			
•		US-			
		US-			
		US-			
		US-			
<del>-</del>		US-			
		US-	<del> </del>		
		US-	<del>                                     </del>		
		US-	<del>                                     </del>		
		US-			
		US-	<del> </del>		
		US-			
	-	US-	<del>                                     </del>		

			<b>IGN PATENT DOCU</b>	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	₹°
0	B13	WO 00/39111	07-06-2000	Eli Lilly and Co		
	B14	WO 00/39117	07-06-2000	Eli Lilly and Co 16		Ľ
Se /	1	WO 00/39118	07-06-2000	Eli Lilly and Co 17		E
	1	EP 796866A1		Eli Lilly and Co \8	· ·	Ε
		WO 97/49404	12-31-1997	Eli Lilly and Co 19		-
02	B18	WO 00/71493	11-30-2000	Cor Therapeutics		-

Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 

Applicant's unique citation designation number (optional). 

See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 

The include copy of this form with next communication to applicant. 

Applicant's unique citation designation number (optional). 

See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant. 

The include copy of this form with next communication to applicant to applica Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Sheet 4

Signature

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code <sup>2 (# known)</sup>			Figures Appear
	1	US-		<del>-</del>	
		US-			
		US-			
		US-		-	
		US-			
		US-	1		
		US-			
		US-	1		
	-	US-	·		
		US-			
		US-			
		US-	<del>                                     </del>		
		US-			
		US-			
		US-			
		US-	<del>                                     </del>		
·		US-			
		US-			-
	-	US-			<del> </del>

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	 
80/	<del>1</del>	Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known) WO 00/71507	11-30-2000	l		E
1800	B20	WO 00/71508	11-30-2000	Cor Therapeutics VL		
200	B21	WO 99/25686 <b>*</b>	05-27-1999	Teijin Ltd 13	Example 2099	E
						L
Examiner	<u> </u>			Date	121610	_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Date

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

/.	E JCI	30
10	'	
/\	Mr 0 .	E WARK
	PATENT 8	TRAD

Approved for use through 04/30/2003. OMB 468 70039.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE revork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 10/030,188

CHOCK BE 20/33

Childry, J. W. Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) **Examiner Name** Patel, Sudhaker B Sheet Attorney Docket Number of 5 00217/US

F	0.1	NON PATENT LITERATURE DOCUMENTS	
	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Jones, Stuart D, et al., Bioorganic & Medicinal Chemistry Letters 11 (2001) 733-736	

Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.